AI Article Synopsis
- The study aimed to analyze how apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-HDL cholesterol (non-HDL-C) relate in high-risk patients on lipid-lowering therapy.
- It compared LDL-C and non-HDL-C levels after treatment with either a statin alone or a combination therapy at the end of the study.
- Findings showed that while treatment improved LDL-C and non-HDL-C levels, only a little over 50% of patients achieving LDL-C or non-HDL-C targets also had an Apo B level under the desired threshold, suggesting Apo B could push for stricter lipid management criteria.
Article Abstract
Objective: To evaluate relationships between apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-HDL-C in high-risk patients treated with lipid-lowering therapy.
Design And Methods: This post-hoc analysis calculated LDL-C and non-HDL-C levels corresponding to an Apo B of 0.9 g/L following treatment with 1) statin monotherapy (baseline) and 2) ezetimibe/simvastatin 10/20mg or rosuvastatin 10mg (study end). The percentages of patients reaching LDL-C, non-HDL-C, and Apo B targets were calculated at study end.
Results: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Only slightly >50% of the patients who reached minimum recommended LDL-C or non-HDL-C at study end also had an Apo B level <0.9 g/L with both treatments.
Conclusion: The use of Apo B for monitoring the efficacy of lipid-altering therapy would likely lead to more stringent criteria for lipid lowering.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinbiochem.2011.02.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!